ESTROGEN/PROGESTERONE (ER/PR) RECEPTOR, IMMUNOHISTOCHEMISTRY (IHC)

Message

This test is ordered by pathologists.Guiding decisions on hormonal therapy in patients with carcinoma

Test Code

1230300848

CPT Codes
88342-TC, primary (Qualitative), 88360 (Quantitative)

Preferred Specimen

Tissue

Methodology
Immunohistochemistry (IHC)

FDA Status
This test has been cleared or approved by the U.S. Food and Drug Administration and is used per manufactureer's instructions. Performance characteristics were verified by WVUH in a manner consistent with CLIA requirements.

Clinical Significance

Estrogen receptor (ER) and progesterone receptor (PR), are steroid hormone receptors commonly used in managing women with breast cancer. ER and PR status provide an indication of prognosis and of the potential benefit from hormonal therapy. Generally, ER/PR-positive tumors are more likely to respond to endocrine therapy and have a better prognosis, stage-for-stage, than receptor-negative tumors. The test is infrequently used for non-breast cancer specimens.

Performing Laboratory
West Virginia University Hospitals, Inc.

The CPT Codes provided in this document are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed. Any Profile/panel component may be ordered separately. Reflex tests are performed at an additional charge.